C18orf21

Across TCGA pan-cancer cohorts, C18orf21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C18orf21 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C18orf21 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated C18orf21 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where C18orf21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.664	1.000	.018	13	view →
LSCC	DFS	Tertile	All	0.848	1.000	.020	4	view →
PDAC	OS	Tertile	IV	0.934	0.472	.024	3	view →
GBM	DFS	Quartile	All	0.644	0.823	.023	2	view →
LUAD	OS	Median	All	0.655	0.903	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C18orf21–CCRCC (OS)

Open the CCRCC breakdown →